SC35 Antibody (YA1905)(PBS only)

Cat. No.: HY-P82160A: Data Sheet User Guide for Antibodies
FAQs
Technical Support

SC35 Antibody (YA1905) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SC35.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

SC35 Antibody (YA1905) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SC35.

Host

Rabbit

Molecular Weight

Predicted band size: 25 kDa;

Observed band size: 35 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Rat

SwissProt ID

Q01130

Gene ID

6427 [NCBI]

Immunogen

A synthetic peptide of human SC35 aa60-73.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:1000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:50-1:100
IP IP: Immunoprecipitation	1:20

Purity	Affinity Purified	Conjugation	Non-conjugated
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment

Subcellular Localization：Nucleus; Nucleus, nucleoplasm; Nucleus speckle

Expression：
Induction:Accumulates in a hypoacetylated/phosphorylated form in response to cisplatin treatment

Isoforms & Post-Translational Modification：Q01130 has 2 isomers: Q01130-1: 25476 Da (predicted); Q01130-2: 24153 Da (predicted).
Extensively phosphorylated on serine residues in the RS domain. Phosphorylated by SRPK2 and this causes its redistribution from the nuclear speckle to nucleoplasm and controls cell fate decision in response to cisplatin treatment. KAT5/TIP60 inhibits its phosphorylation by preventing SRPK2 nuclear translocation;Acetylation on Lys-52 by KAT5/TIP60 promotes its proteasomal degradation. This effect is counterbalanced by HDAC6, which positively controls SRSF2 protein level by deacetylating it and preventing its proteasomal degradation

Subunit：Interacts with BRDT (By similarity). In vitro, self-associates and binds SRSF1/SFRS1 (ASF/SF2), SNRNP70 and U2AF1 but not U2AF2. Binds SREK1/SFRS12. Interacts with CCNL1 and CCNL2. Interacts with SCAF11. Interacts with ZRSR2/U2AF1-RS2. Interacts with CCDC55 (via C-terminus)

Research Field

Epigenetics and Nuclear Signaling

Synonyms

Protein PR264; Splicing component; 35 kDa; Splicing factor SC35; SC-35; Splicing factor; arginine/serine-rich 2

Documentation

User Guide for Antibodies (1077 KB)